Effect of Current Magnitude and Drug Concentration on lontophoretic Delivery of Octreotide Acetate (Sandostatin®) in the Rabbit
- 1 January 1994
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 11 (12) , 1742-1746
- https://doi.org/10.1023/a:1018963300092
Abstract
The effect of current magnitude and drug concentration on transdermal iontophoretic delivery of octreotide acetate (Sandostatin®) was examined in the rabbit. Plasma samples were collected over 24 hours and octreotide concentrations were determined by a radioimmunoassay. Without an electrical current, negligible plasma concentrations of octreotide were obtained. Following initiation of iontophoresis, plasma concentrations of octreotide increased rapidly, although did not sustain at a plateau level during the dosing period. Octreotide concentrations declined rapidly after removal of the device. Increasing the electrical current from 50 µA/cm2 to 150 µA/cm2 yielded a proportional increase in the delivery. Increasing the drug concentration in the device from 2.5 mg/mL to 5 mg/mL resulted in approximately proportional increase in plasma octreotide concentrations; however, further increase in plasma concentrations was not observed for drug concentrations beyond 5 mg/mL. lontophoretic delivery at the conditions which yielded the highest octreotide concentrations in this study (5 mg/mL solution at 150 µA/cm2 for 8 hours) yielded an apparent bioavailability (which represents an underestimate of the absolute bioavailability determined when the patches are run to exhaustion) of approximately 8%.Keywords
This publication has 15 references indexed in Scilit:
- Facilitated Transdermal Transport of InsulinJournal of Pharmaceutical Sciences, 1987
- Noninvasive Delivery of a Novel Inotropic Catecholamine: Iontophoretic versus Intravenous Infusion in DogsJournal of Pharmaceutical Sciences, 1987
- Comparison Between the Lontophoretic and Passive Transport of Thyrotropin Releasing Hormone Across Excised Nude Mouse SkinJournal of Pharmaceutical Sciences, 1986
- Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administrationActa Endocrinologica, 1986
- Pharmacokinetics of SMS 201-995 in Healthy SubjectsScandinavian Journal of Gastroenterology, 1986
- Long-Term Treatment of Acromegaly with the Somatostatin Analogue SMS 201–995New England Journal of Medicine, 1985
- Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.Gut, 1985
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982
- Distribution and metabolism of exogenous somatostatin in the ratRegulatory Peptides, 1982
- Mathematical Basis of Point–Area Deconvolution Method for Determining In Vivo Input FunctionsJournal of Pharmaceutical Sciences, 1978